Study of an injection for active lupus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests an investigational injection called CM313 for people with active lupus (systemic lupus erythematosus). It aims to see if the drug can help reduce lupus symptoms and control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have a confirmed diagnosis of systemic lupus erythematosus (SLE), often called lupus.
- Your lupus must be active, meaning you have a certain level of disease activity as measured by a standard scoring system.
- You must have had a positive test for certain antibodies (like ANA or anti-dsDNA) that are typical in lupus.
- You must be on a stable treatment plan for lupus for at least 30 days before starting the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SHR-2173 for people with active lupus. It aims to see if it can reduce disease activity when taken with standard treatments.
This trial tests an investigational drug called MIL62 for people with systemic lupus erythematosus (SLE) that is still active despite standard treatments. The goal is to see if MIL62 can better control disease activity.
This study tests a new medicine, IMC-002, for people with active lupus that hasn't been controlled by standard treatments. It aims to see if the drug can reduce lupus activity and improve symptoms.
This study tests an experimental injection called ZM001 for people with severe lupus that hasn't improved with standard treatments. The goal is to see if this new therapy can help control the disease.
This study tests an experimental daily pill (BI 3000202) for people with active lupus (SLE) to see if it can reduce disease activity. It compares different doses against a placebo, and you must already be on stable lupus background treatment.
This trial is testing a new investigational drug called QLS4131 in people with systemic lupus erythematosus (SLE), an autoimmune disease where the immune system attacks healthy tissues. The goal is to see if it is safe and effective in reducing disease activity.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.